Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Nov 8, 2020; 11(5): 79-92
Published online Nov 8, 2020. doi: 10.4292/wjgpt.v11.i5.79
Published online Nov 8, 2020. doi: 10.4292/wjgpt.v11.i5.79
Figure 4 Baseline serum levels of transforming growth factor in naïve rats and in poly-lactic acid encapsulated transforming growth factor treated rats.
Blood was taken from naïve Sprague-Dawley rats (males and females, 6 per sex) before and after treatment with poly-lactic acid encapsulated transforming growth factor (TGF). Animals were treated by gavage at doses of 5, 15 or 30 mg/kg, 3 × per week for 25 d. Serum levels of TGFβ were determined by ELISA without acid activation (R&D Systems Quantikine ELISA Catalog# MB100B). Statistical significance (P ≤ 0.02) vs day 25 at 5 mg/kg vs day 25 at 30 mg/kg. All differences between day 0 pre-dose and day 25 pre-dose were significant (P ≤ 0.01). TGFβ: Transforming growth factor .
- Citation: Hammer L, Furtado S, Mathiowitz E, Auci DL. Oral encapsulated transforming growth factor β1 reduces endogenous levels: Effect on inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2020; 11(5): 79-92
- URL: https://www.wjgnet.com/2150-5349/full/v11/i5/79.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i5.79